Clinical trials: Cancer of the Liver
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics…
- Conditions
- Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma
- Trial name
- NCT05293496
- Testing
- vobramitamab duocarmazine, lorigerlimab
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- MacroGenics
Hepatocellular Carcinoma
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00976170
- Testing
- GC33(RO5137382), Sorafenib
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 42 people
- Sponsor
- Chugai Pharmaceutical
Hepatocellular Carcinoma
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
- Trial name
- NCT00627042
- Testing
- Ramucirumab (IMC-1121B)
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma (HCC)
Computer Guided Microwave Liver Ablation
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults.
- Trial name
- MWA Sim (NCT07226869)
- Testing
- Computer-Assisted Microwave Liver Ablation
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- NE Scientific INC
Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
- Trial name
- NCT02240433
- Testing
- LY2157299, Sorafenib
- Where
- 3 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
SynOV1.1 Intratumoral Injection Study
This is a Phase I, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1 in participants…
- Trial name
- NCT04612504
- Testing
- SynOV1.1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Syngentech Co., Ltd.
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Carcinoma, Hepatocellular
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma…
- Trial name
- NCT03062358
- Testing
- pembrolizumab, best supportive care (BSC)
- Where
- 41 sites in China, Hong Kong and 3 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
Hepatic Xenetix-CT Perfusion
The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in…
- Trial name
- NCT01639703
- Testing
- Xenetix-CT perfusion imaging
- Where
- 5 sites in Austria, Germany and 2 more
- Volunteers
- 96 people
- Sponsor
- Guerbet
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe…
- Conditions
- Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03916627
- Testing
- cemiplimab, Platinum Doublet, fianlimab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumours
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab…
- Trial name
- IMFINZI-subQ (NCT07391670)
- Testing
- SC durvalumab + rHu, IV durvalumab, Tremelimumab
- Where
- 19 sites in Australia, Georgia and 3 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Liver Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
- Trial name
- NCT02013830
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 7 sites in Australia, Hong Kong and 2 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer Metastatic
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy.
- Trial name
- EPOCH (NCT01483027)
- Testing
- TheraSphere
- Where
- 131 sites in United States, Austria and 11 more
- Volunteers
- 428 people
- Sponsor
- Boston Scientific Corporation
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Carcinoma, Hepatocellular, Liver Neoplasms
Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis
The purpose of this study is to determine if the, MR guided, laser interstitial thermal therapy (LITT) treatment technique can be safety and efficiently used for the human liver metastasis
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms
- Trial name
- NCT00392366
- Testing
- MR-guided Laser Interstitial Thermal Therapy System
- Where
- France
- Volunteers
- 25 people
- Sponsor
- BioTex, Inc.
Carcinoma, Hepatocellular
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC.
- Trial name
- NCT05908786
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 14 sites in United States, Austria and 4 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with…
- Trial name
- SKYSCRAPER-14 (NCT05904886)
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 171 sites in United States, Belgium and 25 more
- Volunteers
- 687 people
- Sponsor
- Hoffmann-La Roche